Free Stock Performance Review on Thermo Fisher Scientific and Three Additional Medical Research Stocks

Stock Research Monitor: SYNH, TTOO, and BRKR

LONDON, UK / ACCESSWIRE / June 29, 2018/ If you want a free Stock Review on TMO sign up now at www.wallstequities.com/registration. Today, WallStEquities.com has selected the following Medical Laboratories and Research stocks for observation: Syneos Health Inc. (NASDAQ: SYNH), T2 Biosystems Inc. (NASDAQ: TTOO), Thermo Fisher Scientific Inc. (NYSE: TMO), and Bruker Corp. (NASDAQ: BRKR). Medical laboratories are independent, commercial enterprises that provide information to the healthcare professionals about the severity, onset, and reason of patients’ physical ailments. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Syneos Health

Raleigh, North Carolina headquartered Syneos Health Inc.’s stock finished Thursday’s session 0.54% higher at $46.85 with a total trading volume of 515,834 shares. Over the last month and the previous three months, the Company’s shares have advanced 9.21% and 31.97%, respectively. The stock is trading above its 50-day and 200-day moving averages by 10.97% and 8.54%, respectively. Moreover, shares of Syneos Health, which operates as an integrated biopharmaceutical solutions company in North America, EMEA region, Asia/Pacific, and Latin America, have a Relative Strength Index (RSI) of 60.13.

On June 21st, 2018, Syneos Health and Elligo Health Research, the only platform that brings clinical research direct to clinical health care, announced that they are entering a strategic collaboration to mobilize a system of accelerated research to reach real-world patients. Both companies share a vision to evolve the clinical trial paradigm to speed the delivery of biopharmaceutical therapies to market. Get the full research report on SYNH for free by clicking below at:

www.wallstequities.com/registration/?symbol=SYNH

T2 Biosystems

Shares in Lexington, Massachusetts headquartered T2 Biosystems Inc. climbed 1.01%, ending yesterday’s session at $8.00 with a total trading volume of 375,629 shares. The stock has gained 3.36% in the past month, 23.27% in the previous three months, and 130.55% over the past year. The Company’s shares are trading 2.89% above their 50-day moving average and 42.14% above their 200-day moving average. Moreover, shares of T2 Biosystems, which develops diagnostic products and product candidates in the US, have an RSI of 47.57.

On June 01st, 2018, research firm Leerink Partners upgraded the Company’s stock rating from ‘Market Perform’ to ‘Outperform’.

On June 25th, 2018, T2 Biosystems announced that it has been added to the broad-market Russell 3000® Index. The addition occurred at the conclusion of trading on June 22nd, 2018, and was effective after the US market opened on June 25th, 2018. Find your free research report on TTOO at:

www.wallstequities.com/registration/?symbol=TTOO

Thermo Fisher Scientific

On Thursday, Waltham, Massachusetts headquartered Thermo Fisher Scientific Inc.’s stock rose 1.10%, to close the day at $205.61. A total volume of 1.01 million shares was traded. The Company’s shares have advanced 16.98% over the past year. The stock is trading 1.04% above its 200-day moving average. Additionally, shares of the company, which provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide, have an RSI of 39.77.

On June 26th, 2018, Thermo Fisher Scientific announced that it will release its financial results for Q2 before the market opens on July 25th, 2018. The Company will hold a conference call on the same day at 8:30 a.m. EDT. The call can be accessed live under the Investors section of the Company’s website. Sign up today for the free research report on TMO at:

www.wallstequities.com/registration/?symbol=TMO

Bruker

Shares in Billerica, Massachusetts headquartered Bruker Corp. ended the day 1.22% lower at $29.06. A total volume of 1.31 million shares was traded, which was above their three months average volume of 600,820 shares. The stock is trading below its 50-day moving average by 4.95%. Furthermore, shares of Bruker, which manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the US, Europe, Asia/Pacific, and internationally, have an RSI of 35.67.

On June 18th, 2018 at the International Society of Magnetic Resonance in Medicine Conference, Bruker announced the launch of the next version of its preclinical imaging software, ParaVision 360. ParaVision 360 is the most advanced research-grade software for preclinical MRI, and has now also been extended to nuclear molecular imaging. It enables sequential or simultaneous PET/MR measurements and analysis in one user-friendly environment. Wall St. Equities’ research coverage also includes the downloadable free report on BRKR at:

www.wallstequities.com/registration/?symbol=BRKR

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 504097

Go Top